IdoAmitLab

What if we could turn the tumor’s deadliest tricks against it? New @Cancer_Cell: Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Led by @GalYagel, @D_Rimini & @MVLocquenghien (1/15) cell.com/cancer-cell/ab…

Beautiful and important work from Aaron, colleagues, and the Adimab team. If we are still missing such a basic property of therapeutic antibodies, imagine how much of Ab mechanism of action we still do not fully understand, and how much more could be achieved if we did.

@Mayer46231196 @Cancer_Cell @GalYagel @D_Rimini @MVLocquenghien Thank you! 🙏🏻

@IdoAmitLab @Cancer_Cell @GalYagel @D_Rimini @MVLocquenghien This is very interesting. Congratulations

What if we could turn the tumor’s deadliest tricks against it? New @Cancer_Cell: Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Led by @GalYagel, @D_Rimini & @MVLocquenghien (1/15) cell.com/cancer-cell/ab…

@SabanLab This is absolutely beautiful 😻Congratulations Danny for pushing the limits of eye immunity!

We are excited to share that our team's paper is published in Immunity: "Resident tissue macrophages maintain intraocular pressure homeostasis." This work grew out of a collaboration between glaucoma clinician-scientist Katy Liu MD PhD, glaucoma physiologist W. Daniel Stamer PhD, and immunologist Daniel Saban PhD, bringing together clinical, physiological, and immunological expertise to tackle a long-standing question: does the immune system directly regulate intraocular pressure? The answer is yes. authors.elsevier.com/a/1mkeB3qNrV3V… #Glaucoma #Immunology #ResidentMacrophages #Ophthalmology #Immunity #CellPress cell.com/immunity/fullt…

@MiriYagelS1961 @cancercell @GalYagel @D_Rimini @Cancer_Cell Thank you Ima, Yagel power! 💪

@IdoAmitLab @cancercell @GalYagel @D_Rimini Congratulations @Cancer_Cell, what an excellent choice of a beautiful design for the March 2026 issue cover. Congratulations @IdoamitLab @GalYagel @D_Rimini, for being chosen by Cancer Cell journal, to represent the important research of your article on the march issue.

Thank you @CancerCell for featuring our cover! 🐝 Inspired by honeybee “social immunity” where colonies detect and manage sick nestmates, we engineered TME-regulated armored TREM2 CAR T cells to unmask and dismantle immunosuppressive niches in solid tumors @GalYagel @D_Rimini

Thank you @lai9uan and @FGinhoux for highlighting our reaserch! Congratulations for the new Vita journal and team!

Fantastic meeting and lineup, looking forward!

Thank you Brenda and Jason @ImmunoPodcast for this fun discussion. I see a very exciting future for immunology!

📢 We have a new episode out! We chat with Dr. Ido Amit (@IdoAmitLab) at @WeizmannScience about his research applying cutting edge single-cell #genomics technologies to uncover immune regulatory mechanisms and pathways. 🎧 Listen now: bit.ly/40muGA2

@joshpacini These are exciting news, a lot of potential and possibilities

Can’t wait for Valinor’s models to be applied to accelerating the diagnosis and treatment of patients with neurological diseases like Alzheimer’s, Parkinson’s, and ALS. We are working with Renew to generate the most robust multimodal datasets available for these conditions.

@metapredict You clearly know little other than composing overly confident posts.

@IdoAmitLab Nonsense. First, there's no +ve control drug for AD model benchmarking- there are for these 2 (although there are far better examples eg hypertension). AD there's nada. You clearly know little other than composing overly confident posts

Data-driven decision making in drug development is crucial more than ever. Thank you for this important editorial! nature.com/articles/s4159…

@metapredict Models for AD are not better or worse than autoimmune or cancer models. What matters is what we can learn from them. All models are wrong, but some are useful.

@IdoAmitLab lol, it's as if clear mechanisms were established for decades of successful drugs (how niave). No, there were useful preclinical models to guide the programs. The same isn't true for neuroscience where eg TG models of AD done in species that don't show "natural" AD pathology...

@ZelzerLab Beautiful flowers and people!

Nothing like fresh air and the coastal iris in bloom 🌸 #labtrip

@IanParish_AU Beautiful story Ian and co.

TCF1 is a master regulator of T cell stemness – but can it make exhausted cells go backwards? We setup a CRISPR KI system to ask this question, and the answer was unexpected. nature.com/articles/s4146…

ReThink Neuroimmunology (RTN 2026) is coming: Oct 26–28, 2026! Abstract submissions are open for Travel Fellowships + Selected Talks (oral presentations). If you’re in neuroimmunology, don’t miss this. 🔗 conferences.weizmann.ac.il/RTN2026

@erturklab @jonykipnis @boskovic_p Thank you Ali!! 😊

@IdoAmitLab @jonykipnis @boskovic_p Wow that is a nice piece!

Excited to share two back-to-back studies with @jonykipnis @boskovic_p showing the promise of CAR T beyond cancer — in Alzheimer’s and stroke — inspired by the visionary work of Zelig Eshhar.

@WeizmannScience @EranElinav Mazal Tov to the Elinavs x2 and co. for this beautiful work. Absolute dream team!

A study conducted in Israel and Ethiopia, led by researchers at the Weizmann Institute of Science and Hadassah, reveals that the microbiome partly compensates for the immune damage caused by the viral infection>> bit.ly/gut-hiv-eng @EranElinav

@biorxivpreprint A framework for reparative CAR T engineering in the CNS @IdoAmitLab @Rotem_Shalita @M_BenYehudaG @WeizmannScience @jonykipnis @WashU biorxiv.org/content/10.648… 🇮🇱🇺🇸

@LabWaggoner @biorxivpreprint @Rotem_Shalita @M_BenYehudaG @WeizmannScience @jonykipnis @WashU Thank you Stephen for highlighting our work! 🙏🏻